Type II Diabetes Mellitus Clinical Trial
Official title:
Effect of GLP-1 Receptors Agonist Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
Primary Objective:
To evaluate the ability of lixisenatide to modulate postprandial hyperlipidemia in
particular, the effects on plasma changes in triglycerides.
Secondary Objectives:
The effect of lixisenatide on the following postprandial lipids: apolipoprotein (APO) B48;
free fatty acid, lipoprotein distribution, cholesterol, and low-density lipoprotein (LDL)
oxidation.
The effect of lixisenatide on chronic low-grade inflammation present in non-insulin
dependent diabetes mellitus (NIDDM) and obesity.
The effect of lixisenatide on microvascular dysfunction. To evaluate the effect of
lixisenatide on postprandial plasma glucose, insulin and C-peptide and glucagon.
Maximum study duration of approximately 2.5 months (study treatment) ± 2 days Day 0 (baseline) plus a 10-week open-label, active-controlled treatment period (Final/End-of-treatment Visit). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01952535 -
A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01196728 -
Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes
|
Phase 1 | |
| Terminated |
NCT00997152 -
Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients
|
Phase 2 | |
| Completed |
NCT02592421 -
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
|
Phase 3 | |
| Completed |
NCT05544214 -
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01969084 -
The Effect of Linagliptin on Mitochondrial and Endothelial Function
|
Phase 4 | |
| Terminated |
NCT01644201 -
A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics
|
Phase 3 | |
| Completed |
NCT01020123 -
Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients
|
Phase 2 | |
| Completed |
NCT00995787 -
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
|
Phase 1 | |
| Completed |
NCT01505426 -
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients
|
Phase 3 | |
| Completed |
NCT01262586 -
Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.
|
Phase 3 | |
| Completed |
NCT00561171 -
Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria
|
Phase 2 | |
| Recruiting |
NCT03912363 -
Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids
|
N/A | |
| Completed |
NCT01868646 -
Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus
|
Phase 4 | |
| Not yet recruiting |
NCT06386328 -
A Clinical Trial to Evaluate the Food Effect of CKD-378
|
Phase 1 | |
| Terminated |
NCT02749435 -
A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus
|
N/A | |
| Completed |
NCT00894868 -
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
|
Phase 4 | |
| Recruiting |
NCT01165190 -
Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans
|
N/A | |
| Completed |
NCT01255085 -
Yellow Pea Protein and Fibre and Short Term Food Intake
|
N/A | |
| Completed |
NCT02156349 -
A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.
|
N/A |